Elutia (Elutia) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Elutia Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Elutia is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Elutia's Risk Assessment

For the Medical Devices subindustry, Elutia's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elutia's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Elutia's Risk Assessment falls into.

Elutia (NAS:ELUT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Elutia Risk Assessment Related Terms

Thank you for viewing the detailed overview of Elutia's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Elutia (Elutia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904

Website

https://www.aziyo.com

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Executives

Elutia Pipe Investment, Lp	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc	10 percent owner	688 PINE STREET, BURLINGTON VT 05401
Thomas Englese	officer: Chief Commercial Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman	director	452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson	officer: Chief Financial Officer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams	officer: Chief Scientific Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck	10 percent owner	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp	10 percent owner	688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards	officer: GENERAL COUNSEL	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015